PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 16, 2026Journal of Translational Medicine0 citationsOpen Access

MLDP-AS: an optimized next-generation sequencing assay for enhanced detection of technically challenging variants in expanded carrier screening

View Full Paper
ZZZhenhua ZhaoGZGanye ZhaoSLShaojun Li

Key Points

  • The study aims to enhance detection of technically challenging genetic variants in expanded carrier screening using a novel NGS assay.
  • Developed the MLDP-AS assay based on Multiplex Long-Distance PCR and Amplicon Sequencing.
  • Validated assay sensitivity against gold-standard methods using positive clinical samples.
  • Conducted a prospective trial with couples planning or undergoing pregnancy.
  • Achieved 100% sensitivity, identifying all 255 pathogenic variants in known positive samples.
  • Detected overall carrier rate of 22.15% among 5,209 individuals in the trial.
  • Demonstrated a positive predictive value of 99.7% compared to gold-standard methods.

Abstract

Next-generation sequencing (NGS) facilitates simultaneous carrier screening for multiple single-gene disorders. However, conventional NGS methods struggle to detect complex variants, such as F8 inversions, CYP21A2 variations, and single-exon copy number variations (CNVs), resulting in residual risk. We developed and validated MLDP-AS (Multiplex Long-Distance PCR followed by Amplicon Sequencing), a novel NGS assay, to screen for pathogenic variants in ten prevalent single-gene disorders in the Chinese population, including alpha- and beta-thalassemia, non-syndromic hearing loss, spinal muscular atrophy, Duchenne muscular dystrophy, phenylketonuria, 21-hydroxylase deficiency, Wilson disease, methylmalonic acidemia, and Hemophilia A. MLDP-AS detects routine variants and technically challenging types, such as F8 intron 22 inversions, CYP21A2 variations, and single-exon CNVs, in a single test. The assay was optimized using positive clinical samples, with sensitivity validated against gold-standard methods. Clinical applicability was evaluated through a prospective study of couples planning or undergoing pregnancy, with positive results confirmed by gold-standard techniques. MLDP-AS achieved 100% sensitivity, identifying all 255 pathogenic variants in known positive samples, including 36 technically challenging variants. In a prospective trial involving 5, 209 individuals, carriers for all targeted disorders were detected, with an overall carrier rate of 22. 15%. Thirty-four couples (1. 09%) were identified as at-risk, spanning seven of the ten diseases. A total of 289 pathogenic variants were detected 1, 290 times, including 169 technically challenging variants. The assay demonstrated a positive predictive value of 99. 7% compared to gold-standard methods. MLDP-AS is rapid and cost-effective, completing testing within three days at a cost under 25. MLDP-AS integrates detection of multiple complex variants into a single, comprehensive assay, overcoming limitations of conventional NGS. It significantly enhances variant detection and provides an efficient, cost-effective tool for carrier screening in the Chinese population.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Zhao et al. (2026) studied this question.

synapsesocial.com/papers/69926a620d0ce0adc9976a48https://doi.org/10.1186/s12967-026-07735-9
Ask AI
Helpful
Bookmark
Share
View Full Paper